Cecilia Zhang

Graduated from National University of Singapore (NUS), Dr. Cecilia Zhang has been engaged in the R&D and translational research of cancer immunotherapy. As Director and Chief Scientific Officer of Biosyngen, a Singapore-based biotech, Dr. Zhang is now leading a team to develop several next generation CAR-T, TCR-T and allogenic cell therapy pipelines to fill the unmet needs in cancer treatment, including nasopharyngeal carcinoma, gastrointestinal cancers, EB (Epstein-Barr) virus-positive lymphoma, etc. Dr. Zhang is also the owner of multiple renowned academic paper publications and patents of the field. Currently, Biosyngen has obtained IND clearance targeting nasopharyngeal cancer and EBV+ lymphomas by both US FDA and China NMPA. The first in class immunotherapy asset is also granted the orphan drug and fast track designation from FDA. Home to scientific research talents from Singapore, China, Germany, Australia and France, Biosyngen is committed to develop cutting-edge immune cell therapies to benefit cancer patients worldwide.